Table II.

Analysis of disease parameters for active EAE in CD5WT, CD5KO, and CD5ΔCK2BD mice induced with different doses of MOG_35-55 peptide

MOG35-55 Peptide Dose	Mouse Strain	Day of Onset	Time to Peak	Accumulative Score	Incidence	Mortality
50 μg	CD5WT	15.0±1.9a	18.6±4.0e	44.5±10.4e	20/20	1/20
	CD5KO	19.0±5.0b	20.2±4.4	29.8±11.7b	12/15	0/15
	1 CD5ΔCK2BD	19.2±5.2b	20.0±4.2	35.1±14.3b	14/17	2/17
150 μg	CD5WT	12.5±1.5	15.8±3.6	59.5±8.7f	19/19	4/19
	CD5KO	17.2±4.2b	18.6±3.2b	34.6±14.8b	15/15	1/15
	CD5ΔCK2BD	12.9±2.9	17.2±6.9	48.8±4.9b,d	15/15	2/15
450 μg	CD5WT	13.1±3.2	19.0±6.2	45.4±18.5	11/12	0/12
	CD5KO	14.7±2.7c	18.9±4.3	44.3±9.7	11/12	0/12
	CD5ΔCK2BD	13.4±1.7d	17.7±2.7	52.5±11.7d	9/10	0/10

Data are presented as mean ± SEM (n=10-20 mice).

No scores were assigned following day of death.

^ap<0.05; CD5WT 50 μg dose vs. CD5WT 150 μg dose or CD5WT 450 μg dose

^bp<0.05; vs. CD5WT mice at same dose

^cp<0.05; CD5KO 450 μg dose vs. CD5KO 50 μg dose

^dp<0.05; vs. CD5ACK2 50 μg dose

^ep<0.05; CD5WT 50 μg dose vs. CD5WT 150 μg dose

^fp<0.05; CD5WT 150 μg dose vs. CD5WT 450 μg dose